Cahill represented the lead arrangers in the transaction.BioMarin Pharmaceutical Inc. completed an amendment to the $200,000,000 revolving credit facility. Proceeds from the credit facility will be used…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
